Pharmaceutical giant, AbbVie (ABBV), continues to attract the attention of investors. The firm’s consistent dividends have given it a strong foothold in the market, underlined by a series of organizational buy-ins and upgrades from several leading financial institutions like Berenberg and Guggenheim. These firms reiterate a buy rating for AbbVie, with price targets set around $227 and $235 respectively. AbbVie's stock continues to see a rise, even in a falling market, suggesting financial stability and robust market performance.
Following its recent Rinvoq Litigation win, BMO raised their price target to $240. AbbVie's shares have been sold and bought by multiple capital firms, balancing the stock's activity. The company's price target set a new high after the analyst upgrade and its cancer treatments, Epcoritamab and Mirvetuximab, are receiving regulatory approval.
An agreement with generic drugmakers on Rinvoq and Health Canada's approval of ELAHERE are key events that have the potential to drive AbbVie’s valuation. The company's acquisition of Bretisilocin, a potential therapy for Major Depressive Disorder, signals expansion of the Psychiatry Pipeline, widening AbbVie's therapeutic portfolio.
Abbvie ABBV News Analytics from Thu, 05 Jun 2025 07:00:00 GMT to Sat, 20 Sep 2025 13:49:40 GMT - Rating 8 - Innovation 3 - Information 8 - Rumor -4
